CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 18, 2015--
NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company
focused on harnessing the power of the innate immune system by using
natural killer cells to treat cancer, infectious diseases and
inflammatory diseases, today announced that it has been added to the
NASDAQ Biotechnology Index® (NBI) as part of NBI’s annual
selection of biotechnology and pharmaceutical companies listed on the
NASDAQ Stock Market® that meet NBI’s eligibility criteria.
NantKwest will be added to the NBI effective prior to market open on
December 18, 2015.
The NASDAQ Biotechnology Index is a modified market capitalization
weighted index that is designed to track the performance of a set of
securities listed on The NASDAQ Stock Market® (NASDAQ®)
that are classified as either biotechnology or pharmaceutical according
to the Industry Classification Benchmark and is re-ranked annually in
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest's NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest's NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information please visit ýhttp://www.nantkwest.com
and follow Dr. Soon-Shiong on Twitter@solvehealthcare.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151218005101/en/
Source: NantKwest, Inc.
Jen Hodson, 562-397-3639